2005
Selected Abstracts from the EASL
Conference – April 13-17, 2005 Paris, France
Click here
for important information on how to read an abstract
Hepatitis B
HBV Treatment
Current Therapies-
- COST-EFFECTIVENESS OF TWO ORAL ANTIVIRAL
THERAPIES, LAMIVUDINE AND ADEFOVIR DIPIVOXIL OF HBEAG-NEGATIVE CHRONIC
HEPATITIS B (April 16, 2005)
- Adefovir
- PREDICTORS OF A PEJORATIVE OUTCOME IN
PATIENTS TREATED WITH ADEFOVIR DIPIVOXIL FOR REACTIVATION OF CHRONIC
HEPATITIS B DUE TO LAMIVUDINE-RESISTANT HEPATITIS B VIRUS MUTANTS (April
16, 2005)
- ADEFOVIR DIPIVOXIL (ADV) DEMONSTRATES SUSTAINED EFFICACY
IN HBEAG- CHRONIC HEPATITIS B (CHB) PATIENTS (April
16, 2005)
- Special Populations
- Entecavir
- LACK OF A PHARMACOKINETIC
INTERACTION WHEN ENTECAVIR IS CO-ADMINISTERED WITH LAMIVUDINE, ADEFOVIR,
OR TENOFOVIR (April 16, 2005)
- ENTECAVIR (ETV) RESISTANCE IS NOT
OBSERVED IN NUCLEOSIDE-NAÏVE SUBJECTS AND IS OBSERVED INFREQUENTLY BY
WEEK 48 IN LAMIVUDINE-REFRACTORY SUBJECTS WITH CHRONIC HBV INFECTION (April
16, 2005)
- ENTECAVIR (ETV) IS SUPERIOR TO
LAMIVUDINE AND ADEFOVIR IN TRIALS OF HBEAG-POSITIVE AND -NEGATIVE CHRONIC
HEPATITIS B INFECTION: A
CROSS-STUDY ANALYSIS WITH PUBLISHED REPORTS (April
16, 2005)
- SUSTAINED RESPONSE OFF-TREATMENT TO
ENTECAVIR AND LAMIVUDINE AFTER 48 WEEKS OF TREATMENT IN NUCLEOSIDE-NAÏVE,
HBEAG(+) PATIENTS: 24-WEEK FOLLOW-UP RESULTS OF PHASE 3 STUDY ETV-022
(April 16, 2005)
- ALANINE AMINOTRANSFERASE (ALT) FLARES
ARE UNCOMMON BOTH ON- AND POST-TREATMENT IN ENTECAVIR TREATED HBEAG(+)
PATIENTS (April 16, 2005)
- Renal Impairment
- Lamivudine
- LAMIVUDINE THERAPY FOR SEVERE ACUTE
HEPATITIS B (April 16, 2005)
- HBEAG NEGATIVE PATIENTS WITH CHRONIC
HEPATITIS B ARE LESS LIKELY TO HAVE A BIOCHEMICAL BREAKTHROUGH DURING
LAMIVUDINE TREATMENT (April 18, 2005)
- Special Populations
- Children
Diagnostic Tools –
Disease Progression –
- FACTORS ASSOCIATED WITH LIVER DECOMPENSATION IN
PATIENTS WITH CHRONIC HEPATITIS B (April 16,
2005)
- VIRAL LOAD IS A STRONG PREDICTOR OF LIVER CIRRHOSIS
RISK IN PEOPLE CHRONICALLY INFECTED WITH HEPATITIS B VIRUS REGARDLESS OF
HEPATITIS B E ANTIGEN STATUS (April 16,
2005)
- VIRAL LOAD AS A PREDICTOR OF MORTALITY FROM
HEPATOCELLULAR CARCINOMA AND CHRONIC LIVER DISEASE IN CHRONIC HEPATITIS B
INFECTION (April 16, 2005)
- PROGRESSION TO DECOMPENSATED CIRRHOSIS IN CHRONIC
HEPATITIS B VIRUS INFECTED PERSONS IS STRONGLY ASSOCIATED WITH BASELINE
VIRAL LOAD (April 16, 2005)
Epidemiology
- CHARACTERISTICS OF HEPATITIS B VIRUS
(HBV) INFECTED PATIENTS IN FRANCE: A CROSS-SECTIONAL MULTICENTER STUDY OF
406 PATIENTS (April 18, 2005)
Experimental Therapies–
- Hepavir B
- Interferon based therapies
- Pegasys
- EFFECT
OF GENOTYPE AND OTHER BASELINE FACTORS ON RESPONSE TO PEGINTERFERON
ALFA-2A (40KD) (PEGASYS®) IN HBEAG-POSITIVE CHRONIC HEPATITIS B: RESULTS
FROM A LARGE, RANDOMISED STUDY (April 16,
2005)
- ON-TREATMENT
PREDICTORS OF SUSTAINED BIOCHEMICAL AND VIROLOGICAL RESPONSE IN PATIENTS
WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B (CHB) TREATED WITH PEGINTERFERON
ALFA-2A (40KD) (PEGASYS®) (April 16,
2005)
- GREATER
VIRAL SUPPRESSION WITH LAMIVUDINE +/- PEGINTERFERON ALFA-2A (PEGASYS®)
DOES NOT TRANSLATE INTO IMPROVED RATES OF SUSTAINED HBEAG
SEROCONVERSION: RESULTS FROM A LARGE, MULTINATIONAL STUDY (April
16, 2005)
- SUSTAINED
HBSAG SEROCONVERSION IN PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH
PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) (April 16,
2005)
- PEGINTERFERON
ALFA-2A (40KD) (PEGASYS®) VERSUS PEGINTERFERON ALFA-2A PLUS LAMIVUDINE
VERSUS LAMIVUDINE IN HBEAG-POSITIVE CHRONIC HBV: EFFECT OF PREVIOUS
TREATMENT AND DRUG EXPOSURE ON SUSTAINED RESPONSE (April
16, 2005)
- SUSTAINED
RESPONSE TO PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) IN HBEAG-NEGATIVE
CHRONIC HEPATITIS B. 1-YEAR
FOLLOW-UP DATA FROM A LARGE, RANDOMISED MULTINATIONAL STUDY (April
16, 2005)
- EFFECT
OF ALT FLARES ON EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A (40KD)
(PEGASYS®), PEGINTERFERON ALFA-2A PLUS LAMIVUDINE AND LAMIVUDINE IN
HBEAG-POSITIVE CHRONIC HEPATITIS B (CHB) (April 16,
2005)
- Peg-Intron
- QRT-PCR
ANALYSIS OF TELOMERASE MRNA EXPRESSION IN LIVER BIOPSY SPECIMENS IN
PATIENTS WITH HEPATITIS B AND C UNDERGOING ANTIVIRAL THERAPY (April 16,
2005)
- SEQUENTIAL
COMBINATION OF PREDNISONE, LAMIVUDINE AND INTERFERON ALPHA 2B FOR HBEAG
POSITIVE CHRONIC HEPATITIS B: A RAMDOMIZED AND CONTROLLED PILOT STUDY (April 16,
2005)
- COMBINATION
THERAPY OF PEGINTERFERON ALFA-2B AND ADEFOVIRDIPIVOXIL IN CHRONIC
HEPATITIS-B LEADS TO A STRONG SUPPRESSION OF CCCDNA AND HIGH RATES OF
HBE AND HBS SEROCONVERSION (April
16, 2005)
- FLARES
IN CHRONIC HEPATITIS B PATIENTS INDUCED BY THE HOST OR THE VIRUS?
RELATION TO TREATMENT RESPONSE DURING PEG-INTERFERON ALPHA-2B THERAPY (April 16,
2005)
- Gamma Interferon
- HEPATIC FIBROSIS IN PATIENTS WITH
CHRONIC HEPATITIS B VIRUS INFECTION CAN BE PARTIALLY REVERSED BY
IFN-GAMMA (April 16, 2005)
- Standard Interferon
- LDT
- Pediatrics
- Telbivudine
- HBV VIRAL DYNAMICS OF TELBIVUDINE VS.
LAMIVUDINE AND THE COMBINATION: RELEVANCE OF EARLY VIRAL SUPPRESSION TO
BETTER LONG-TERM CLINICAL RESPONSE (April 16,
2005)
- Tenofovir
- SUCCESSFUL THERAPY OF CHRONIC HEPATITIS
B WITH TENOFOVIR IN HBV-MONOINFECTED AND IN HIV-COINFECTED PATIENTS
FAILING PREVIOUS ADEFOVIR AND LAMIVUDINE TREATMENT (April
18, 2005)
- FREQUENCY OF HBEAG LOSS AND LONG-TERM
ANTIVIRAL SUPPRESSION UNDER NUCLEOS(T)IDE TREATMENT IN HBEAG POSITIVE
CHRONIC HEPATITIS B (April 18, 2005)
Genotype–
- CLINICAL SIGNIFICANCE OF HEPATITIS B VIRUS
GENOTYPES IN KOREA :THE FIRST LARGE-SCALE KOREAN STUDY (April
16, 2005)
- WHAT DOES THE HEPATITIS B VIRUS DNA
LEVEL TELL US IN HBEAG-NEGATIVE PATIENTS INFECTED WITH HBV GENOTYPE D ?
(April 18, 2005)
Occult HBV–
- OCCULT HEPATITIS B VIRUS INFECTION IS
ASSOCIATED WITH CARCINOGENESIS OF HEPATOCELLULAR
CARCINOMA IN PATIENTS WITH LIVER CIRRHOSIS IN CHRONIC HEPATITIS C VIRUS
CARRIERS (April 16, 2005)
- OCCULT HBV INFECTION IN PATIENTS WITH
CHRONIC HEPATITIS C AND IN HCV/HIV COINFECTED PATIENTS (April
18, 2005)
- OCCULT HEPATITIS B VIRUS INFECTION IN A
COHORT OF HIV POSITIVE PATIENTS (April 18,
2005)
Transmission–
Treatment–
Viral Kinetics–
HIV/HBV Coinfection
Current Therapies-
- Interferon based therapies
Disease Severity
- FACTORS ASSOCIATED WITH THE SEVERITY OF
HBV-RELATED CHRONIC HEPATITIS IN HIV-INFECTED PATIENTS (April
18, 2005)
Experimental Therapies–
- IS TENOFOVIR PLUS LAMIVUDINE SUPERIOR TO
TENOFOVIR MONOTHERAPY IN PATIENTS WITH HBV/HIV COINFECTION? (April
18, 2005)
Interferon based therapies
Occult HBV–
- OCCULT
HBV INFECTION IN PATIENTS WITH CHRONIC HEPATITIS C AND IN HCV/HIV
COINFECTED PATIENTS (April 18, 2005)
- OCCULT
HEPATITIS B VIRUS INFECTION IN A COHORT OF HIV POSITIVE PATIENTS (April
18, 2005)
Steatosis–
Transplantation–